Leukocytose optrådte hos 50% af patienter med APL, vurderet ud fra en hæmatologisk bedømmelse frem for fra indberettede bivirkninger.
Leukocytosis occurred in 50% of patients with APL, as determined by haematology assessments, rather than adverse event reports.